Belviq will become the second obesity bet to be launched in the market within a year. VIVUS, Inc. (NASDAQ : VVUS ) 's Qsymia is already available through mail order and specialty pharmacies. The only key player still waiting for an FDA approval is Orexigen Therapeutics, Inc. (NASDAQ : OREX ) with its candidate Contrave.